Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20759392 | 0.82 | SMN1; SMN2 (0.38) | KDM4EGAAMAPT | |
| SCHEMBL2756573 | 0.81 | NPC1 (0.34) | GAA | |
| SCHEMBL16709295 | 0.81 | CASR (0.31) | — | |
| SCHEMBL23896980 | 0.80 | — | — | |
| SCHEMBL13080783 | 0.78 | NPC1 (0.44) | GAA | |
| SCHEMBL21104585 | 0.77 | TRPV1 (0.42) | — | |
| SCHEMBL16711657 | 0.74 | MKNK1 (0.33) | MAPT | |
| SCHEMBL16709294 | 0.73 | LMNA (0.31) | — | |
| SCHEMBL15935300 | 0.73 | EGFR (0.31) | — | |
| SCHEMBL13587141 | 0.71 | POLB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475783-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150031694-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2015-01-29 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8415383-B2 | Substituted benzamidines as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-04-09 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | KDM4E 819/4885GAA 2923/4885MAPT 4688/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | KDM4E 2407/4885GAA 4454/4885MAPT 4784/4885 |
| US-20150031694-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ABCB11 | KDM4E 3955/4885GAA 2221/4885MAPT 4735/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | KDM4E 1251/4885GAA 3241/4885MAPT 4744/4885 |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | ALK, CBR3, CBR1 | KDM4E 2671/4885GAA 3748/4885MAPT 4838/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | KDM4E 2407/4885GAA 4454/4885MAPT 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.